Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Check with your doctor if you have any of the following: A mole that: changes in size, shape, or color
[1] [5] Research into transdermal delivery of peptide medications faces significant challenges due to the large molecular size of GLP-1 analogs and the skin's natural barrier function
Separation by time of day prevents problematic interactions
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
Nagy, C
Erythroid cells in immunoregulation: characterization of a novel suppressor factor
US$ 26.08
US$ 21.12
US$ 26.20
US$ 21.64
US$ 26.74
US$ 21.31
US$ 23.82
US$ 23.78
US$ 23.00
US$ 26.25
US$ 29.34
US$ 25.03
US$ 21.39
US$ 29.03
US$ 26.37
US$ 25.90
